We observed significant tumor growth inhibition after 3 weeks of treatment with Cmpd-43, and just like we saw with genetic deletion of Prl2, we found that pharmacologic inhibition of PRL2 suppresses Akt signaling through PTEN augmentation to inhibit tumor cell proliferation with no effect on apoptosis in the thymic lymphomas. The gene discussed is AKT1; the disease is thymus lymphoma.